DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer

被引：27

作者：

Alexander, Brian M. ^{[1
,2
]}

Sprott, Kam ^{[3
]}

Farrow, D. Allan ^{[3
]}

Wang, XiaoZhe ^{[3
]}

D'Andrea, Alan D. ^{[1
]}

Schnitt, Stuart J. ^{[4
]}

Collins, Laura C. ^{[4
]}

Weaver, David T. ^{[3
]}

Garber, Judy E. ^{[5
]}

机构：

[1] Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[2] Harvard Radiat Oncol Program, Boston, MA USA

[3] On Q Ity Inc, Waltham, MA USA

[4] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA

[5] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

来源：

CLINICAL CANCER RESEARCH | 2010年 / 16卷 / 23期

关键词：

FANCONI-ANEMIA; HOMOLOGOUS RECOMBINATION; INCREASED SENSITIVITY; MAPKAP KINASE-2; CISPLATIN; MUTATIONS; SUBTYPES; DAMAGE; CELLS; GENE;

D O I：

10.1158/1078-0432.CCR-10-0292

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To evaluate the prognostic utility of immunohistochemical assessment of key proteins in multiple DNA repair pathways in triple-negative breast cancer (TNBC; estrogen receptor negative, progesterone receptor negative, and HER2/neu negative by immunohistochemistry). Experimental Design: Archived clinically annotated tumor specimens from 112 women with TNBC were immunostained with antibodies against DNA repair proteins and scored using digital image analysis. The cohort was divided into training and test sets for development of a multiantibody model. Scores were combined with clinical data to assess association with outcome. Results: Low XPF (P = 0.005), pMK2 (P = 0.01), MLH; P = 0.002), and FANCD2 (P = 0.001) were each associated with shorter time to recurrence (TTR) in univariate analysis. A 4-antibody model could segregate high-risk and low-risk groups on the basis of TTR in both the training (relative risk [RR] = 3.52; P = 9.05E-07) and test (RR 2.67; P = 0.019) cohorts. Conclusions: DNA repair proteins may be useful as prognostic markers in TNBC. Further study in larger, uniformly treated cohorts with additional clinical parameters is warranted. Clin Cancer Res; 16(23); 5796-804. (C)2010 AACR.

引用

页码：5796 / 5804

页数：9

共 56 条

[41]

O'Shaughnessy J, 2009, J CLIN ONCOL, V27

[42] DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy [J].

Olaussen, Ken A. ;

Dunant, Ariane ;

Fouret, Pierre ;

Brambilla, Elisabeth ;

Andre, Fabrice ;

Haddad, Vincent ;

Taranchon, Estelle ;

Filipits, Martin ;

Pirker, Robert ;

Popper, Helmut H. ;

Stahel, Rolf ;

Sabatier, Laure ;

Pignon, Jean-Pierre ;

Tursz, Thomas ;

Le Chevalier, Thierry ;

Soria, Jean-Charles .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (10) :983-991

[43] Breast cancer molecular subtypes respond differently to preoperative chemotherapy [J].

Rouzier, R ;

Perou, CM ;

Symmans, WF ;

Ibrahim, N ;

Cristofanilli, M ;

Anderson, K ;

Hess, KR ;

Stec, J ;

Ayers, M ;

Wagner, P ;

Morandi, P ;

Fan, C ;

Rabiul, I ;

Ross, JS ;

Hortobagyi, GN ;

Pusztai, L .

CLINICAL CANCER RESEARCH, 2005, 11 (16) :5678-5685

[44] Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers [J].

Sakai, Wataru ;

Swisher, Elizabeth M. ;

Karlan, Beth Y. ;

Agarwal, Mukesh K. ;

Higgins, Jake ;

Friedman, Cynthia ;

Villegas, Emily ;

Jacquemont, Celine ;

Farrugia, Daniel J. ;

Couch, Fergus J. ;

Urban, Nicole ;

Taniguchi, Toshiyasu .

NATURE, 2008, 451 (7182) :1116-U9

[45] Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma [J].

Sakai, Wataru ;

Swisher, Elizabeth M. ;

Jacquemont, Celine ;

Chandramohan, Kurapaty Venkatapoorna ;

Couch, Fergus J. ;

Langdon, Simon P. ;

Wurz, Kaitlyn ;

Higgins, Jake ;

Villegas, Emily ;

Taniguchi, Toshiyasu .

CANCER RESEARCH, 2009, 69 (16) :6381-6386

[46] Triple-Negative Breast Cancer: Risk Factors to Potential Targets [J].

Schneider, Bryan P. ;

Winer, Eric P. ;

Foulkes, William D. ;

Garber, Judy ;

Perou, Charles M. ;

Richardson, Andrea ;

Sledge, George W. ;

Carey, Lisa A. .

CLINICAL CANCER RESEARCH, 2008, 14 (24) :8010-8018

[47] Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS [J].

Sgagias, MK ;

Wagner, KU ;

Hamik, B ;

Stoeger, S ;

Spieker, R ;

Huber, LJ ;

Chodosh, LA ;

Cowan, KH .

CELL CYCLE, 2004, 3 (11) :1451-1456

[48] A novel diagnostic screen for defects in the Fanconi anemia pathway [J].

Shimamura, A ;

Oca, RMC ;

Svenson, JL ;

Haining, N ;

Moreau, LA ;

Nathan, DG ;

D'Andrea, AD .

BLOOD, 2002, 100 (13) :4649-4654

[49] Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease [J].

Sijbers, AM ;

deLaat, WL ;

Ariza, RR ;

Biggerstaff, M ;

Wei, YF ;

Moggs, JG ;

Carter, KC ;

Shell, BK ;

Evans, E ;

deJong, MC ;

Rademakers, S ;

deRooij, J ;

Jaspers, NGJ ;

Hoeijmakers, JHJ ;

Wood, RD .

CELL, 1996, 86 (05) :811-822

[50] Repeated observation of breast tumor subtypes in independent gene expression data sets [J].

Sorlie, T ;

Tibshirani, R ;

Parker, J ;

Hastie, T ;

Marron, JS ;

Nobel, A ;

Deng, S ;

Johnsen, H ;

Pesich, R ;

Geisler, S ;

Demeter, J ;

Perou, CM ;

Lonning, PE ;

Brown, PO ;

Borresen-Dale, AL ;

Botstein, D .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (14) :8418-8423

← 1 2 3 4 5 6 →